Alzheimer's Disease Management Guideline: Update 2008

Segal‐Gidan, Freddi; Cherry, Debra; Jones, R; Williams, Bradley R.; Hewett, Linda; Chodosh, Joshua

doi:10.1016/j.jalz.2010.07.005

Cited by 38 publications

(27 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous crosssectional studies indicate that up to 44% of individuals with AD or dementia have sleep disturbances (Vitiello and Borson, 2001;Lyketsos et al, 2002). The first-line treatment of sleep problems for individuals with AD are nonpharmacological, including sleep hygiene practices, stimulation during the day, reduction of excessive stimulation, and/or noise in the evening (Segal-Gidan et al, 2011). Many clinical care guidelines alleviate the importance of nonpharmacological approaches (Rabins et al, 2007;Finnish Medical Society Duodecim, Helsinki, 2010).…”

Section: Discussionmentioning

confidence: 99%

Long-term use of benzodiazepines and related drugs among community-dwelling individuals with and without Alzheimer’s disease

Taipale¹,

Koponen²,

Tanskanen

et al. 2015

International Clinical Psychopharmacology

View full text Add to dashboard Cite

The aim of this study was to investigate the prevalence of benzodiazepine and related drug (BZDR) use, especially long-term use, and associated factors among community-dwelling individuals with and without Alzheimer's disease (AD). We utilized data from the MEDALZ-2005 cohort, which includes all community-dwelling individuals diagnosed with AD in Finland at the end of 2005 and matched comparison individuals without AD. Register-based data included prescription drug purchases, comorbidities, and hospital discharge diagnoses. In this study, 24,966 individuals with AD and 24,985 individuals without AD were included. During the 4-year follow-up, we found that 45% (N = 11,312) of individuals with AD and 38% (N = 9534) of individuals without AD used BZDRs. The prevalence of long-term (≥ 180 days) BZDR use was more common among individuals with AD (30%) than individuals without AD (26%). The median durations of the first long-term use periods of BZDRs were 1.5 and 2 years for individuals with and without AD, respectively. Factors associated with long-term BZDR use included female sex, AD, schizophrenia, bipolar disorder, depression, coronary artery disease, and asthma/chronic obstructive pulmonary disease. The high prevalence of long-term BZDR use among individuals with AD is especially a cause for concern because long-term use may further impair cognition and may be associated with serious adverse events.

show abstract

Section: Discussionmentioning

confidence: 99%

Long-term use of benzodiazepines and related drugs among community-dwelling individuals with and without Alzheimer’s disease

Taipale¹,

Koponen²,

Tanskanen

et al. 2015

International Clinical Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…The list of components in the text box is summarized from multiple guidelines published over the past 15 years and these components are reflected in the content of recently tested models of care; these key components are rather consistent across guidelines and these components have changed little over time. (40–43)…”

Section: Basic Components Of Best Practice Modelsmentioning

confidence: 99%

Redesigning Systems Of Care For Older Adults With Alzheimer’s Disease

et al. 2014

View full text Add to dashboard Cite

The basic principle of care for patients with Alzheimer's disease is support for a patient-caregiver dyad. Any model of care seeking to improve the quality, efficiency, or cost of care for persons with Alzheimer's disease must attend to this principle. Models of care seeking to support this dyad began with strategies focusing mainly on the family caregiver. These models have grown in complexity to encompass team-based care that seeks to coordinate care across settings and providers of care for a defined population of patients. Most Americans in most communities, however, do not have access to these best practices models. While the effectiveness of new models of care is evidence-based, there are multiple barriers to widespread adoption including workforce limitations and the cost of practice redesign. We review the origins and content of current models and describe early efforts to improve their implementation on a broader scale.

show abstract

“…The steps include a description of the behavior (D) that includes timing, location, people involved, and detailed characteristics of the behavior. Investigation of causes (I) addresses the patient, caregiver, and environmental factors involved and includes medical sources that should be ruled out especially in an acute onset where they are commonly implicated [53,54]. Creating a plan (C) involves development of targeted strategies to address the behavior and underlying causes.…”

Section: Frameworkmentioning

confidence: 99%

“…Several professional organizations have suggested that drug therapy should be used only after the failure of non-pharmacological strategies or in cases of grave danger or distress [26,54,56] and that these strategies should be specifically targeted to stage of dementia [57]. For the purpose of discussion, we have divided these strategies into categories of environmental, caregiver, and behavioral approaches.…”

Section: Non-pharmacological Strategiesmentioning

confidence: 99%

Non-pharmacological Management of Behavioral Symptoms in Frontotemporal and Other Dementias

Barton

Ketelle

Merrilees

et al. 2016

FOC

View full text Add to dashboard Cite

Worldwide prevalence of dementia is predicted to double every 20 years. The most common cause in individuals over 65 is Alzheimer's disease (AD), but in those under 65, frontotemporal dementia (FTD) is as frequent. The physical and cognitive decline that characterizes these diseases is commonly accompanied by troublesome behavioral symptoms. These behavioral symptoms contribute to significant morbidity and mortality among both patients and caregivers. Medications have been largely ineffective in managing these symptoms and carry significant adverse effects. Non-pharmacological interventions have been recommended to precede the utilization of pharmacological treatments. This article reviews the research about these interventions with special attention to the variations by etiology, especially FTD. The authors offer recommendations for improving utilization of these strategies and future research recommendations.

show abstract

Alzheimer's Disease Management Guideline: Update 2008

Abstract: The Guideline recommendations provide a framework to inform and improve medical care for AD by primary health care providers.

Cited by 38 publications

References 52 publications

Long-term use of benzodiazepines and related drugs among community-dwelling individuals with and without Alzheimer’s disease

Long-term use of benzodiazepines and related drugs among community-dwelling individuals with and without Alzheimer’s disease

Redesigning Systems Of Care For Older Adults With Alzheimer’s Disease

Non-pharmacological Management of Behavioral Symptoms in Frontotemporal and Other Dementias

Contact Info

Product

Resources

About